

January 21, 2020

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001.

To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

**Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

This is to inform you that the Board of Glenmark Pharmaceuticals Limited (the "Company") at its meeting held today approved the transaction, the details of which are mentioned in the **Annexure A**.

The said Annexure is pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to kindly take note of the same.

Thanking You.

Yours faithfully,  
For Glenmark Pharmaceuticals Ltd.



**Harish Kuber**  
**Company Secretary & Compliance Officer**

Encl: As above

**Annexure A**

**Details which a listed entity needs to disclose for Sale or disposal of unit(s) or division(s) or subsidiary of the listed entity under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:**

a) the amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	The turnover of the Gynaecology business in India & Nepal for the year ended March 31, 2019 was less than 1% of the turnover of Glenmark Pharmaceuticals Ltd. on standalone basis
b) date on which the agreement for sale has been entered into	21 <sup>st</sup> January, 2020
c) the expected date of completion of sale/disposal	On or before 31 <sup>st</sup> March, 2020
d) consideration received from such sale/disposal	Valued at Rs. 115 Crores, subject to various transaction costs and other adjustments
e) brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	Integrace Pvt. Ltd.  Buyer does not belong to the promoter/ promoter group companies
f) name of the entity(ies), details in brief such as, size, turnover etc.	Integrace Pvt. Ltd having its registered office at Rocklines House, Ground Floor, 9/2, Museum Road, Bengaluru – 560001  Integrace Pvt. Ltd is a portfolio company of the PE firm, True North. It has presence in the Ortho & pain management therapy areas in India
g) whether the transaction would fall within related party transactions? If yes, whether the same is done at “arms length”	It is not a related party transaction
h) area of business of the entity(ies)	Pharmaceuticals Marketing & Distribution
i) rationale	This will stimulate growth for the Gynaecology business in the new entity
j) in case of cash transaction – amount or otherwise share exchange ratio	Cash consideration
k) Brief details of change in shareholding (if any) of listed entity	No change in shareholding pattern of the Company

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

